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INTRODUCTION
The incidence of  brain metastasis (BM) is 
reported to be increase about 20-40% over the 
last few years in patients with non-small-cell 
lung cancer (NSCLC).1 The use of  epidermal 
growth factor receptor (EGFR) tyrosine kinase 
inhibitor (TKI) in NSCLC patients with BM, 
especially those harboring EGFR mutations 
have been reported.
CASE REPORT 
A 56-year-old woman with the initial 
major complaint of  persistent and progressive 
headache within the last 4 months. Within the 
last 1 year before she sometimes complained 
of  mild to moderate headache that still allowed 
her to work. She had seeked for medication to 
several private hospitals before then reffered 
to our hospital. A head computed tomography 
(CT)-scan confi rmed multiple lesion in the 
frontal area (January 29 2013) (Figure 1). She 
was admitted into our hospital with worsening 
symptoms of  consciousness and unable to 
communicate either passively or actively since 
the last days before hospitalization. Other 
imaging finding was a suspected mass in 
the lung eventhough the patient had never 
complained for any respiratory problems 
(Figure 2)  
Figure 1. A head computed tomography 
(CT)-scan confi rmed multiple lesion in 
the frontal area
Her initial condition urged a salvage 
craniotomy for mass evacuation on February 
6th 2013. Pathology examination revealed 
in a metastatic adenocarcinoma. She was 
discharged a week after the operation in a 
stable condition. She returned to Sardjito 
hospital in May 2013 with the other complaint 
of  dyspneu and cough, after visiting a private 
hospital and had a thorax-CT which confi rmed 
a lung mass of  the medial lobe of  the left lung 
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(Figure 3). An ultrasound guided fi ne needle 
aspiration confi rmed a diagnosis of  Non Small 
Cell Carcinoma. The EGFR mutation analysis 
from the fine needle aspiration revealed a 
deletion at exon 19. 
Figure 3. Lung mass of  the left medial 
lobe (3.3x2cm) 
 
She also felt that the headache got 
progressive in the last one month. Evaluation 
of  head CT Scan showed multiple brain 
metastasis of  the frontal area (Figure 4).
The administration of  EGFR-TKI 
(Gefi tinib) was started in May 23 2013. The 
following imaging for evaluation showed 
improvements of  the brain and lung (Figure 
5a and b).
The patient kept on consuming Gefi tinib 
for 16 months (May 2013- September 2014). 
During this period the patient mostly had a good 
cognitive function, and good daily functional 
and social life. However, her husband informed 
that she recently sometimes complained 
of  slight headache and forgetfulness. Head 
MSCT was done with result of  multiple brain 
metastasis  of  the left frontal lobe with midline 
Figure 2a and b. Suspected lung mass of  the left medial lobe (2.5x2cm)
Figure 4. Multiple brain metastasis in 
the frontal area. Shifting of  the midline 
to the right of  1 cm
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shifting to the right (Figure 6). Thorax MSCT 
resulted in stable disease for partial response (d 
0.7cm) as compared to the result in September 
2013 (Figure 7).
DISCUSSION
Non-small-cell lung cancer (NSCLC) is 
still the leading cause of  cancer-related death 
worldwide, mainly due to its high incidence 
and late diagnosis. The 20–40% increase in the 
incidence of  brain metastasis (BM) in NSCLC 
patients reported over the last few yearsis 
largely the result of  advances in neuroimaging 
and prolonged survival achieved using new 
treatments.1  BM has long been a major issue 
in clinical practice, since its symptoms lead to a 
signifi cant impairment of  quality of  life and a 
rapid decline in the patient's clinical condition. 
If  untreated, the prognosis of  BM patients is 
poor, with a median survival of  1–2 months.1 
In this case the initial complaints of  the 
patient was persistent headache which gradually 
progressed leading to lack of  consciousness 
and motoric aphasia. The symptoms of  mild to 
moderate headache had started approximately 
Figure 5a. Improvement of  the perifocal edema and lesion in the right frontal area  
(when compared to the result in September 2013), 5b. Two months after routine 
Gefi tinib administration.
Figure 6. Multiple brain metastasis  of  
the left frontal lobe with midline shifting 
to the right
Figure 7. Compared with September 




from one year before getting worsened in the 
last 4 months. 
Several treatments for BM include 
whole-brain radiation therapy (WBRT), long 
considered the cornerstone of  treatment, is 
effective in achieving local disease control and 
a survival prolongation of  4–6 months, with 
an improvement or, at least, a stabilization in 
symptoms, but it is frequently burdened with 
signifi cant comorbidities and side effects. In 
the presence of  one to three brain lesions, 
the treatment of  choice may be gamma knife, 
radiosurgery or surgical removal, which is 
known to prolong survival.2 
In this case a salvage craniotomy for 
mass evacuation was done due to severe 
clinical symptoms of  lack of  consciousness 
and motoric aphasia. 
The efficacy of  chemotherapy in the 
treatment of  patients with BM is limited, 
with data reported in various studies showing 
response rates ranging from 15 to 50%. 
Interestingly, following chemotherapy for BM, 
the response rates achieved are comparable 
with those obtained in systemic disease. 
Nonetheless, the median survival remains 
poor, ranging from 4 to 6 months.3  
The blood–brain barrier (BBB) is an 
anatomic structure consisting of  endothelial 
vessel cells, astrocytes and pericytes with 
tight junctions (TJs) and a number of  carrier 
proteins which controls and limits the passage 
of  molecules to the brain. In the presence of  
an intact BBB, only small lipophilic molecules 
(molecular weight [MW] <400 Da) can cross 
the BBB by diffusion, while the passage of  
other molecules is regulated by the carrier 
proteins.  The loss of  TJs in the tumor 
vascular system in macroscopic intracranial 
lesion does not necessarily incur the loss of  
other biological BBB components, such as 
detoxifi cation and drug resistance mechanisms, 
which may remain effective and compromise 
drug ¬concentrations in BM.4  
Epidermal growth factor receptor 
(EGFR)-dependent pathway plays an important 
role in the development and progression of  
human epithelial cancers, including NSCLC. 
EGFR is expressed on the cell surface of  a 
substantial percentage of  NSCLCs. Activation 
of  the EGFR pathway is able to promote tumor 
growth and progression, stimulating cancer 
cell proliferation, production of  angiogenic 
factors, invasion and metastasis, and inhibiting 
apoptosis.5 EGFR works through two different 
downstream signaling pathways, which are 
activated by the phosphorylation of  the ATP-
binding domain of  the receptor: the MAPK 
cascade, which activates different genes linked 
to cell proliferation and survival; and the 
PI3K–AKT cascade, in which phosphorylated 
AKT inactivates proapoptotic proteins. TKIs 
inhibit the phosphorylation and tyrosine kinase 
activity of  the intracellular domain of  EGFR 
through competitive binding to this site, thus 
preventing the activation of  downstream 
signaling.6 In general, activating EGFR 
mutations are more commonly observed in 
patients with adenocarcinomas and no prior 
history of  smoking, as well as in females and 
those of  Asian descent. 
Initial studies with the EGFR tyrosine 
kinase inhibitors (TKIs) demonstrated biologic 
and clinical activity in only a relatively limited 
subset of  lung cancers. The highest response 
rates to these TKIs were seen in patients 
with somatic mutations within the EGFR-
TK domain, particularly exon 19 deletion, 
exon 21 L858R, and exon 18 G719X.   These 
activating EGFR mutations are associated with 
high response rates to EGFR tyrosine kinase 
inhibitor (TKI) therapy, with combined results 
from 21 studies from 2004 to 2006 showing 
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responses in 210 of  268 patients (78%). These 
response rates observed in patients with 
EGFR-mutant tumors receiving TKIs were 
much higher than what had been described 
in patients treated with standard platinum-
doublet chemotherapy.7 By contrast, the exon 
20 T790M mutation is associated with acquired 
resistance to TKI therapy.8 
In this patient the result of  EGFR 
mutation analysis from the fine needle 
aspiration revealed a deletion at exon 19 
suggesting the administration of  Gefi tinib. 
Lung cancers harboring mutations in 
the epidermal growth factor receptor (EGFR) 
respond to EGFR tyrosine kinase inhibitors, 
but drug resistance invariably emerges. All 
drug-resistant tumors retained their original 
activating EGFR mutations, and some acquired 
known mechanisms of  resistance including 
the EGFR T790M mutation or MET gene 
amplifi cation. Some resistant cancers showed 
unexpected genetic changes including EGFR 
amplifi cation and mutations in the PIK3CA 
gene, whereas others underwent a pronounced 
epithelial-to-mesenchymal transition.9
In this case, the underlying cause of  the 
progression was not yet defi ned. Nonetheless 
any molecular changes is possible. Further 
molecular analysis should be done not only to 
defi ne the mechanism of  resistance but also 
to determine further treatment. 
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